Skip to main content
. 2019 Oct 26;2(4):83. doi: 10.3390/mps2040083

Figure 1.

Figure 1

Workflow showing toolkit for phenotyping hypertrophic cardiomyopathy (HCM) in cellular models. Cardiomyocytes can be obtained from different sources (biopsies or cell lines) and require dissociation into a single cell suspension prior to phenotyping. Evaluation of in vitro hallmarks of HCM is done via: (1) Flow volumetry to investigate hypertrophy; (2) high-content imaging to assess multinucleation, brain natriuretic peptide (BNP) hypertrophic marker expression, and sarcomeric disarray; (3) Seahorse assay and qPCR to assess mitochondrial respiration and content, respectively.